House Committee urges HHS to improve security on medical devices

In a letter written to HHS Acting Secretary Eric D. Hagan, House of Representatives Committee on Energy and Commerce Chairman Greg Walde, R-Oregon, urged the agency to develop a sector-wide plan of action in deploying a “bill of materials” (BOM) for healthcare technology.

Citing the large cyberattacks WannaCry and NotPetya, Walden stated that the lack of visibility in stakeholders knowing what software or hardware is in healthcare technologies is a risk to providing care. In response to these findings, Walden wrote about the Health Care Industry Cybersecurity Task Force’s recommendation of using BOMs to improve the security of medical technology.

“Having a 'bill of materials' is key to organizations to manage their assets because they must first understand what they have on their systems before determining whether these technologies are impacted by a given threat or vulnerability,” wrote the task force in its recommendation. “Moreover, this transparency enables health care providers to assess the risk of medical devices on their networks, confirm components are assessed against the same cybersecurity baseline requirements as the medical device and implement mitigation strategies when patches are not available.”

Walden concluded the letter by asking HHS to arrange efforts into creating a plan to deploy BOMS for healthcare technology as a first step toward improving cybersecurity.

“While the implementation and use of BOMs will not completely protect the health care sector from cyber threats, it is an important, common-sense step towards improving the cybersecurity of the sector overall,” Walden wrote.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.